34 results about "Antithrombotic treatment" patented technology

The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy.

Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against α_IIbβ₃ integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to α_IIbβ₃ integrin or to both α_IIbβ₃ and α_Vβ₃ integrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for α_IIbβ₃ integrin.

The invention relates to compounds which are polysufated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.

The invention relates to the field of medical equipment and specifically relates to a self-adapting wearable anti-thrombus treating device and a control method thereof. The self-adapting wearable anti-thrombus treating device comprises a main engine and a pressure airbag component which is connected with an air channel of the main engine; the pressure airbag component comprises a plurality of multi-cavity pressure airbags independent from each other; the main engine comprises a detection treating module and a control module, wherein the detection treating module is used for detecting the optimal vein suffering pressure and vein refilling time through the multi-cavity pressure airbags; and the control module is used for automatically acquiring the optimal vein suffering pressure and the vein refilling time and taking as the treating pressure and the aerating and deflating air cycle interval time of the pressure airbag component for treating a patient. On the basis of the realization of portability and wearable property, the self-adapting wearable anti-thrombus treating device also can take the automatically detected vein refilling time and vein suffering pressure as a therapeutic schedule to more effectively comply with the rule of human vein blood flow, thereby more effectively realizing anti-thrombus treatment.

The invention relates to pharmaceutical compositions of acetylsalicylic acid-based microcapsules to selectively inhibit the COX in the portal vein and/or in the liver to reduce the production of thromboxane. Further, the pharmaceutical composition minimizes COX inhibition in the systemic circulation to optimize the inhibition of platelet aggregation. Certain embodiments also address methods of prevention and/or treatment of these diseases, using these oral compositions such as enhancing the safety of antithrombotic treatments. Other embodiments contemplate oral pharmaceutical compositions that combine acetylsalicylic acid with anti-platelet aggregation drugs, without inducing gastric side effects.

The present invention describes antibodies generated against platelet membrane glycoprotein VI-(GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research and immunotherapeutic agents, in particular, as antithrombotic therapeutic agents.

The invention discloses an intracranial dense mesh stent with an anticoagulant coating. The intracranial dense mesh stent comprises a dense mesh stent body and a hydrophilic polymer material covering the dense mesh stent body, wherein the dense mesh stent body is coated with the anticoagulant coating. According to the intracranial dense net stent, not only can a channel be reconstructed for blood vessels, but also antithrombotic treatment can be carried out on the blood vessel wall at the position of stent implantation, and embolism treatment can be carried out on aneurysm at the same time.

The invention relates to a compound composition preparation, as well as a preparation method and a use thereof, and particularly relates to a pharmaceutical composition taking clopidogrel and pharmaceutically acceptable salts thereof, as well as atorvastatin calcium as active ingredients, and the preparation method of the pharmaceutical composition. The pharmaceutical composition can be used for preventing and treating cardiovascular and cerebrovascular diseases and performing anti-atherosclerotic and anti-thrombotic treatment, and can further improve the single treatment effect of the clopidogrel and realize the synergy. After the pharmaceutical composition disclosed by the invention is used for preparing a pharmaceutical preparation, the compliance of a patient can be improved.

The new RAPID THROMBOCHEK TEST KIT is based on thrombochek screening test for measurement of hyperaggregable platelets in whole blood, which may be present either in form of circulating platelet aggregates, spontaneously aggregating platelets or reacting to weak agonist of platelet aggregation in low concentration—all together, in order to investigate thrombotic tendencies and to assess the efficacy of antithrombotic therapy all measured with help of hematology cell counter and magnetic stirrer at 37° C. of temperature. This is compared to the other existing microscopic method and shows 0.97% correlation. RAPID THROMBOCHEK TEST KIT based on the above methodology is to be used with the aid of an automated hematology analyser and is made available for routine clinical and office laboratory use.

The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy. The combinations comprise a compound of formula (I) or a pharmaceutically acceptable derivative thereof; formula (I), and another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof.

The invention relates to the technical field of thrombus treatment, and and particularly relates to an antithrombotic traditional Chinese medicine formula. The antithrombotic traditional Chinese medicine formula is prepared from the following raw materials in parts by weight: 10-20 parts of astragalus membranaceus, 5-10 parts of rhizoma atractylodis, 5-10 parts of earthworm, 3-10 parts of ground beeltle, 2-4 parts of leech powder, 4-8 parts of stir-baked squama manitis, 3-10 parts of roasted rhizoma cyperi, 6-12 parts of medicinal cyathula root, 5-10 parts of rhizoma alismatis, 8-12 parts of tuckahoe, 10-18 parts of root of red-rooted salvia, 8-12 parts of angelica sinensis, 8-12 parts of ligusticum wallichii, 8-10 parts of uncaria rhynchophylla and 5-8 parts of pseudo-ginseng. The antithrombotic traditional Chinese medicine formula disclosed by the invention has the effects of benefiting qi for activating blood circulation, removing blood stasis, dispersing phlegm, and activating meridians to stop pain, can effectively relieve symptoms, and delay or control development of the disease, has a significant clinical effect, and is suitable for further popularization and application in clinic; the defect that thrombosis cannot be effectively cured by the pure western medicine can be compensated; a novel effective way is provided for antithrombotic treatment.

The invention relates to pharmaceutical compositions of acetylsalicylic acid-based microcapsules to selectively inhibit the COX in the portal vein and/or in the liver to reduce the production of thromboxane. Further, the pharmaceutical composition minimizes COX inhibition in the systemic circulation to optimize the inhibition of platelet aggregation. Certain embodiments also address methods of prevention and/or treatment of these diseases, using these oral compositions such as enhancing the safety of antithrombotic treatments. Other embodiments contemplate oral pharmaceutical compositions that combine acetylsalicylic acid with anti-platelet aggregation drugs, without inducing gastric side effects.

The invention relates to an application of isorhamnetin as a protease disulfide bond isomerase inhibitor. At a molecular level, isorhamnetin can directly interact with the protein disulfide isomeraseand inhibit a reducing activity of the protein disulfide isomerase. The invention also relates to an application of isorhamnetin in antithrombotic treatment.

The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

The invention discloses application of a salviae miltiorrhizae and flos carthami composition to enhancement of the antithrombotic function of aspirin. On the basis of the traditional Chinese medicine prescription compatibility theory and a large number of experiments and researches, the salviae miltiorrhizae and flos carthami composition is screened out and can remarkably inhibit the esterase activity of aspirin, the hydrolysis speed of aspirin is reduced, the acting time of aspirin is prolonged, aspirin resistance is inhibited, the antiplatelet function of aspirin is enhanced, the antithrombotic treatment effect can be enhanced by clinically using the salviae miltiorrhizae and flos carthami composition and aspirin, adverse effects are reduced, and application prospects are important.

The invention relates to a sensor and capsule integrated biocompatible micro device. The sensor and capsule integrated biocompatible micro device is characterized by comprising a pressure sensor, which is wrapped by biocompatible polymer into an oval capsule; the upper side and the lower side of the front section of the capsule are provided with sensor flexible touch rods; the upper side and the lower side of the middle of the capsule are provided with pipe wall fixing hooks; the upper side and the lower side of the rear section of the capsule are provided with heparin slowly releasing channels; the sensor flexible touch rods are connected with a pressure sensor body; the heparin slowly releasing channels are communicated with the capsule. The sensor and capsule integrated biocompatible micro device has the advantages of being convenient to implant in blood vessel, achieving real-time alarming of thrombogenesis by real-time monitoring intraoperative and postoperative blood pressure andaccordingly the blood pressure change, and achieving antithrombotic drug slow releasing by implanting a system in positions where thrombus is prone to shaping and detecting the blood pressure duringthe easy formation period of thrombus, thereby achieving the aim of antithrombotic treatment.

The invention belongs to the technical field of medicine, and in particular relates to a crystal form of Edoxaban trihydrate and a preparation method thereof. The invention also relates to a pharmaceutical composition containing the above-mentioned crystal form of Edoxaban trihydrate and its preparation method for treating antithrombotic drugs. in the application.

The invention discloses application of glucocorticoid in preparation of a medicine for preventing and treating venous embolism, and belongs to the technical field of medicines. According to the invention, the inhibition effect of GC on NETs is studied by utilizing clinically common medicine glucocorticoid (GC), so that the GC can be applied to new application of VTE treatment, a new strategy is provided for clinical antithrombotic treatment, the strategy can avoid clinical complications, and the method is safe and effective.

The invention discloses a transapical mitral valve stitching instrument. The instrument comprises an outer sleeve, an inner sleeve and an inner sheath which are sequentially nested from outside to inside, the inner sheath comprises a sheath body and a pull wire; elastic valve abutting pieces are arranged on the two sides of the bottom of the sheath body. The bottom end of the sheath body extends downwards to form a pull wire fixing rod; inner sleeve comprises an inner tube, elastic valve supporting pieces are arranged on the two sides of the bottom of the inner tube, and suture pipelines are arranged on the two sides of the inner tube wall of the outer sleeve respectively; a valve suture with a suture fixing head is laid in the suture pipeline; a pull wire fixing head is arranged at an endopening of the elastic valve abutting piece; the valve suture and the pull wire penetrate through the pull wire fixing rod; the two ends of the pull wire are arranged on the pull wire fixing head respectively; and the elastic valve abutting piece and the elastic valve supporting piece are clamped with each other after the inner sheath and the inner sleeve extend out of the lower end of the outersleeve. The instrument is easier to control, small in transapical trauma, fast in postoperative recovery and free of antithrombotic treatment after operation, and avoids thrombus formation and bleeding risks related to the instrument.